The Latest Medical News

A Summary of The Latest Medical News: Menopausal hormone therapy (MHT)—sometimes called hormone replacement therapy—has long been recognized for its ability to counteract the drop in estrogen that occurs at menopause. Estrogen plays a key role in maintaining bone strength, and when levels fall, women become more susceptible to accelerated bone loss and, ultimately, osteoporosis and fractures. Key points about MHT and bone health • 69% lower risk of low bone mineral density: In the study you’re referring to, postmenopausal women using MHT showed a dramatically reduced likelihood of developing low bone mineral density compared with non‐users. • Fracture prevention: By preserving or increasing bone density, MHT can translate into fewer hip, spine, and wrist fractures—injuries that carry significant morbidity in older women. How estrogen affects bone • Bone remodeling balance: Our skeleton is constantly being broken down (resorption) and rebuilt (formation). Estrogen slows the activity of cells that dissolve bone (osteoclasts) and supports cells that build bone (osteoblasts). • Menopausal bone loss: As estrogen levels plummet around menopause, bone resorption outpaces formation, leading to a rapid phase of bone loss in the first 5–10 years after the final menstrual period. Who might benefit from MHT for bone health • Early postmenopausal women (typically under age 60 or within 10 years of menopause) with significant vasomotor symptoms (hot flashes, night sweats) may gain dual benefits—relief of menopausal symptoms plus protection against bone loss. • Women at high risk of osteoporotic fracture who cannot tolerate—or decline—other approved osteoporosis medications (e.g., bisphosphonates). Considerations and precautions • Duration of use: Current guidelines often recommend using MHT at the lowest effective dose for the shortest duration needed to achieve treatment goals, then reassessing risks and benefits. • Risks: MHT may carry potential risks, including blood clots, stroke, and, depending on formulation and patient history, a small increase in breast cancer risk. Those with a history of hormone‐sensitive cancers, unexplained uterine bleeding, or certain clotting disorders may be advised against MHT. • Individualization: The decision to start—or continue—MHT for bone protection should be individualized, weighing personal health history, age, time since menopause, and concurrent risk factors. Alternative and adjunctive options • Nonhormonal osteoporosis treatments: Bisphosphonates, denosumab, selective estrogen receptor modulators (SERMs), and parathyroid hormone analogues are approved specifically for osteoporosis prevention or treatment. • Lifestyle measures: Adequate calcium and vitamin D intake; regular weight‐bearing and muscle‐strengthening exercise; smoking cessation; and moderation of alcohol intake all support bone health. Next steps If you or someone you know is considering MHT primarily for bone health, it’s important to: 1. Discuss personal risk factors for osteoporosis and fracture with a healthcare provider. 2. Review all possible therapies—hormonal and nonhormonal—to find the best fit. 3. Reevaluate periodically, since risks and benefits can change with age and health status. Disclaimer: This information is provided for educational purposes and does not replace personalized medical advice. Always consult your doctor or a qualified health professional before starting or stopping any hormone therapy. Help with your insurance? https://tally.so/r/n012P9